You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 9,061,057


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,061,057 protect, and when does it expire?

Patent 9,061,057 protects CYTALUX and is included in one NDA.

This patent has thirty-five patent family members in twelve countries.

Summary for Patent: 9,061,057
Title:Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Abstract: The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a pteroyl ligand that binds to a target receptor protein, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid or derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.
Inventor(s): Kularatne; Sumith A. (West Lafayette, IN), Mahalingam; Sakkarapalayam M. (West Lafayette, IN), Low; Philip S. (West Lafayette, IN)
Assignee: Purdue Research Foundation (West Lafayette, IN)
Application Number:14/207,130
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 9,061,057

Introduction

When analyzing a patent, it is crucial to delve into its scope, claims, and the broader patent landscape to fully comprehend its implications and significance. This article will provide a detailed analysis of United States Patent 9,061,057, focusing on its claims, the legal framework, and the context within which it exists.

What is a Patent?

Before diving into the specifics of Patent 9,061,057, it is essential to understand what a patent is. A patent is a government grant that gives the inventor exclusive rights to make, use, and sell their invention for a specified period, typically 20 years from the filing date of the patent application[1].

The Role of the USPTO

The United States Patent and Trademark Office (USPTO) is the agency responsible for granting U.S. patents and registering trademarks. The USPTO ensures that patents meet the criteria of novelty, non-obviousness, and usefulness as outlined in the U.S. patent laws[1].

Patent 9,061,057: Overview

To analyze Patent 9,061,057, one must start by identifying the invention it covers. Here are the key components:

Invention Description

Patent 9,061,057 describes an invention that must be identified through the patent's abstract and detailed description. The abstract provides a concise summary of the invention, while the detailed description elaborates on how the invention works and its various embodiments.

Claims

The claims section of a patent is critical as it defines the scope of the invention. Claims are the legal boundaries of what the patent protects. There are two main types of claims: independent claims and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[5].

Analyzing the Claims

Independent Claims

Independent claims in Patent 9,061,057 would outline the broadest scope of the invention. These claims are crucial because they define what is novel and non-obvious about the invention.

Dependent Claims

Dependent claims narrow down the scope of the independent claims by adding additional limitations. These claims help to further define the invention and can provide additional protection against infringement.

Legal Framework

35 U.S.C. § 112

The claims must comply with 35 U.S.C. § 112, which requires that the specification contain a written description of the invention and that the claims particularly point out and distinctly claim the subject matter regarded as the invention. This section ensures that the claims are clear and definite[5].

35 U.S.C. § 251

For reissue patents, 35 U.S.C. § 251 is relevant. This section stipulates that reissue claims must be directed to "the invention disclosed in the original patent." This means that any reissue claims cannot broaden the scope of the original patent beyond what was originally disclosed[5].

Patent Landscape

Prior Art

Understanding the prior art is essential to determine the novelty and non-obviousness of the invention. Prior art includes all publicly available information that existed before the filing date of the patent application. The USPTO uses tools like the Global Dossier and Common Citation Document (CCD) to consolidate and analyze prior art from various patent offices[4].

Competing Patents

Analyzing competing patents in the same field helps in understanding the market and potential infringement issues. This involves searching through existing patents, published patent applications, and other patent documentation using resources like the USPTO Public Search Facility and Patent and Trademark Resource Centers (PTRCs)[4].

Economic and Practical Considerations

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset can provide insights into patent scope and claims trends. This dataset contains detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014. It helps in understanding the broader patent landscape and how claims are structured and analyzed[3].

Small Claims Patent Court

The concept of a small claims patent court, as studied by the Administrative Conference of the United States (ACUS), could impact the enforcement and litigation of patents like 9,061,057. Such a court would aim to provide a more accessible and cost-effective way for inventors to resolve patent disputes[2].

Practical Implications

Enforcement and Litigation

The scope and claims of Patent 9,061,057 determine how it can be enforced and defended in court. Clear and well-defined claims are crucial for successful litigation. Any ambiguities or broad claims that do not comply with legal standards can lead to challenges during enforcement[5].

Licensing and Collaboration

The patent's scope also affects licensing agreements and collaborations. Clear claims help in negotiating licensing terms and ensure that all parties understand what is protected and what is not.

Key Takeaways

  • Claims Definition: The claims section of a patent is crucial as it legally defines the scope of the invention.
  • Legal Compliance: Claims must comply with U.S. patent laws, particularly 35 U.S.C. § 112 and § 251 for reissue patents.
  • Prior Art: Understanding prior art is essential to determine the novelty and non-obviousness of the invention.
  • Patent Landscape: Analyzing competing patents and using tools like the Global Dossier and CCD helps in understanding the market and potential infringement issues.
  • Economic Considerations: The USPTO's Patent Claims Research Dataset and the concept of a small claims patent court can provide valuable insights into patent enforcement and litigation.

FAQs

Q: What is the primary role of the USPTO in the context of patents? A: The USPTO is responsible for granting U.S. patents and registering trademarks, ensuring that patents meet the criteria of novelty, non-obviousness, and usefulness.

Q: How do independent and dependent claims differ in a patent? A: Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims.

Q: What is the significance of 35 U.S.C. § 251 in patent law? A: This section stipulates that reissue claims must be directed to "the invention disclosed in the original patent," ensuring that reissue claims do not broaden the scope beyond what was originally disclosed.

Q: How can the Global Dossier and CCD tools be used in patent analysis? A: These tools consolidate and analyze prior art from various patent offices, providing a single point of access to citation data and file histories of related applications.

Q: What is the purpose of the Patent Claims Research Dataset provided by the USPTO? A: This dataset contains detailed information on claims from U.S. patents and applications, helping in understanding patent scope and claims trends.

Sources

  1. U.S. Patent and Trademark Office (USPTO) | USAGov
  2. U.S. Patent Small Claims Court - ACUS
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO
  5. In Re FLOAT'N'GRILL LLC - Court of Appeals for the Federal Circuit

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,061,057

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes 9,061,057 ⤷  Subscribe Y Y CYTALUX IS AN OPTICAL IMAGING AGENT INDICATED IN ADULT PATIENTS WITH OVARIAN CANCER AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,061,057

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013381391 ⤷  Subscribe
Australia 2013383382 ⤷  Subscribe
Australia 2013383386 ⤷  Subscribe
Australia 2017203340 ⤷  Subscribe
Brazil 112015022810 ⤷  Subscribe
Canada 2902205 ⤷  Subscribe
Canada 2903727 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.